Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARRECTOR: Roflumilast Foam for Scalp Psoriasis
NCT05028582Phase 3Completed
- Sponsor
- Arcutis Biotherapeutics
- Start
- Aug 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of roflumilast in psoriasis, plaque psoriasis, sponsored by Arcutis Biotherapeutics. Started Aug 2021; status: completed.
02
Drugs
roflumilast
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on NCT05028582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05028582.